Contact UsConsumer Site
Product
Technology
Clinical Data
Prescribing
Get Started

iiSure™ Technology

Empowering physicians like you with advanced technology for enhanced patient care in diabetes management.

Breakthrough Features of iiSure™ Technology

Fastest Occlusion Detection1-7

Detect insulin flow issues up to nine times faster than other AID systems, minimizing the risk of prolonged hyperglycemia and potential complications for your patients.2

Precision Insulin Measurement10

Ensure accurate insulin delivery with every dose, giving you confidence in your prescribed treatment plans and potentially improving glycemic outcomes for your patients.

Sound Wave Technology

Leverage cutting-edge acoustic measurement for accuracy in insulin dosing, setting a new standard in diabetes care technology.

The novel iiSure™ technology in the twiist™ Automated Insulin Delivery (AID) System provides unprecedented accuracy and the fastest occlusion detection available.1-7

The technology uses sound waves to directly measure the volume of insulin delivered and includes 4 checkpoints along the way to help ensure accurate delivery—something no other AID system can do.

The Only Device with Sound Wave Technology, Designed to Accurately Measure and Deliver Insulin.1,3-7

As a healthcare provider, you understand the critical importance of accurate insulin dosing. The twiist AID System, powered by iiSure technology, offers people with diabetes personalized control that may significantly impact patient outcomes.

By prescribing twiist, you're providing your patients with a device that not only meets but exceeds current standards in insulin delivery precision. This advanced technology allows for more confident management of your patients' diabetes, potentially leading to improved glycemic control and reduced risk of complications.

iiSure™ Technology—detects occlusions up to 9x faster than other AID systems1-7

Faster time to occlusion detection.
Transform Diabetes Management with the twiist AID System
Get Started
Personalized Diabetes Control
Product
Product Overview
Technology
Tidepool Loop AlgorithmiiSure technology
Clinical Data
Study DataResources
Prescribing
Prescribing twiist
Get Started
Contact Us
INDICATIONS FOR USE

The twiist™ system is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin, ages six and above. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The twiist system is intended for single patient, home use and requires a prescription. 

Loop Indications for Use
Loop is intended for use with compatible integrated continuous glucose monitors (iCGM) and the twiist alternate controller enabled(ACE) insulin infusion pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend, and with the user’s confirmation, deliver correction boluses when glucose values are predicted to exceed user configurable thresholds. Loop is intended for the management of type 1 diabetes mellitus in persons six years of age and greater, and is intended for single-patient use. The twiist automated insulin delivery system is for prescription use only.

Bolus Calculator
Indications for Use
The simple bolus calculator, available when Loop is off, is indicated for use for aiding the user in determining the bolus insulin dosage for management of diabetes mellitus based on consumed carbohydrates, operator-entered blood glucose, insulin sensitivity, carbohydrate ratio, correction range, and current active insulin.
REFERENCES

1. The twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide, Sequel Med Tech: DKPI-09233-001 1.3 2024-02-23.
2. Calculation based on the following sources, reporting 1 U/hr basal rate: Omnipod 5 Technical User Guide (PT-001716-AW Rev03 03/24,) MiniMed 780G System User Guide (M036461C001 2). iLet Bionic Pancreas System User Guide (LA000081_D). Calculation based on the following sources, reporting 2 U/hr basal rate: t:slim X2 Insulin Pump User Guide (AW-1011648_B), Tandem Mobi System User Guide (AW-1012691_A 2023-Dec-07.)
3. Omnipod 5 Technical User Guide. Insulet Corporation: PT-001716-AW Rev. 03 03/24.
4. MiniMed 780G with the Guardian. Sensor System User Guide, Medtronic: M036461C001_2 2023-02-24.
5. t:slim X2 Insulin Pump with Control-IQ Technology User Guide, Tandem Diabetes Care: AW-1011648_B 2023-Nov-09.
6. Tandem Mobi System, Tandem Diabetes Care: AW-1012691_A 2023-Dec-07.
7. iLet Bionic Pancreas System Quick Reference Guide, Beta Bionics: LA000082_E.
8. Lum JW, Bailey RJ, Barnes-Lomen V, et al. A real-world prospective study of the safety and effectiveness of the Loop open source automated insulin delivery system. Diabetes Technol Ther. 2021;23(5):367-375.
9. Wong JJ, et al. Psychosocial Effects of the Loop Open-Source Automated Insulin Delivery System. J Diabetes Sci Technol 2023;17:1440–7.
10. R. D. Butterfield and N. M. Sims, “Performance of a Continuous Subcutaneous Insulin Infusion (CSII) Pump with Acoustic Volume and Flow Sensing in Simulated High Consequence Situations,” in IEEE Open Journal of Engineering in Medicine and Biology, doi: 10.1109/OJEMB.2024.3408092.

CONTRAINDICATIONS

‍

The twiist automated insulin delivery system is not intended for anyone unable or unwilling to:

‍

  • Test blood glucose (BG) levels as recommended by their healthcare provider.
  • Maintain sufficient diabetes selfcare skills.
  • See their healthcare provider regularly.
  • Demonstrate adequate carbohydrate-counting skills (preferred, not required).

The user must not:

‍

  • Have difficulty seeing.
  • Have difficulty hearing.
  • Have deficient cognitive capabilities.
  • Have physical impairments that would make operating the pump or iPhone difficult.
“twiist,” “iiSure,” and the twiist logo are licensed trademarks of Sequel Med Tech, LLC. “Tidepool” and the Tidepool logo are trademarks of Tidepool Project, a fully-qualified 501(c)(3) nonprofit organization.
© 2024 Sequel Med Tech, LLC. All rights reserved.
Privacy Policy   |   Terms of Use